Pfizer — full event log

3R Circular Program prioritizes reduction, reuse, and recycling of high-volume shipment materials (e.g., reusing thermal blankets). Global Circularity Project testing feasibility of reusing packaging in downstream transportation, replacing single-use systems with reusable solutions.

sustainability_report p.32

The 2024 Impact Report does not disclose use of durable carbon removals (DAC, BECCS, biochar) or offset retirements. Pfizer's stated path to net zero by 2040 emphasizes absolute reductions: 95% reduction in Scope 1 & 2 and 90% reduction in value chain emissions from a 2019 baseline. The company describes biodiversity site-level work and tree-planting (e.g., '175 Trees' project resulting in 600+ trees planted) as nature-positive initiatives but does not characterize these as carbon removals or quantify removal credits.

sustainability_report p.30

Reducing GHG emissions from manufacturing and R&D facilities is a key element of reaching net-zero by 2040. Pfizer invests in no- and low-carbon technologies, pursues LEED-certified facilities (NY HQ LEED Platinum, Ringaskiddy/Madrid LEED Gold, Vienna Platinum in 2024), and manages F-gases/refrigerants to limit ozone-depleting and high-GWP materials.

sustainability_report p.31

Pfizer's vehicle fleet, used largely by commercial teams to engage healthcare providers, accounted for ~12% of total Scope 1 GHG emissions in 2024. Pfizer is transitioning to battery electric vehicles (BEVs), with BEVs on the road in 10 markets and plans for additional markets in 2025+. Three electric vehicle tractors and charging stations deployed at Pleasant Prairie, Wisconsin logistics center.

sustainability_report p.31

Target: reduce business travel emissions 25% by 2025 from a 2019 baseline. Travel-related GHG emissions in 2024 were 55% lower than the 2019 baseline (188 ktCO2e vs 421 ktCO2e). Pfizer has implemented digital tools to limit travel and uses preferred carriers advancing GHG targets.

sustainability_report p.30

Scope 3 emissions are ~4x direct operations and procurement of goods and services is the largest contributor. Target: drive 64% of suppliers by spend to set science-based targets by 2025. Currently 65% of suppliers by spend have or have committed to develop SBTs (up 27% vs 2023). In 2024 Pfizer hosted PSCI annual meeting, ran a supplier summit, and launched a training academy for suppliers on measuring/reducing GHG emissions.

sustainability_report p.32

Target: reduce upstream transportation and distribution emissions 10% by 2025 from 2019. In 2024 emissions were 23% lower than the 2019 baseline and 40% lower than 2023. Pfizer's Ocean Program shifts shipments from air to ocean (up to 98% emission reduction per route) and expanded into Indonesia, Egypt, and Australia-to-US. In Europe, biofuels reduced truck shipment emissions by ~32% in 2024; sustainable aviation fuel cuts air emissions ~29%; ocean uses sustainable maritime fuels.

sustainability_report p.32

Pfizer conducted 20+ life cycle assessments across small molecules, large molecules, vaccines, and medical devices. The Pfizer Clear digital tool estimates Scope 3 GHG emissions for packaging, devices, and single-use systems. Transitioning to electronic product information via 2D barcodes, exploring low-carbon aluminum, bio-based plastics, and recycled corrugated packaging.

sustainability_report p.35

Methodological enhancement to how logistics and tertiary packaging material weights are accounted for in upstream transportation; 2023 baseline restated 16% lower.

sustainability_report p.136

Pfizer added well-to-wheel emissions for air travel to Scope 3 Category 6 in alignment with GHG Protocol. 2023 air travel emissions were restated upward by ~8%.

sustainability_report p.136

Pfizer's Scope 3 GHG footprint is approximately four times that of its direct operations; procurement of goods and services (Cat 1) represents 78% of total Scope 3. Pfizer's SBTi-validated supplier engagement target requires 64% of suppliers by spend to adopt science-based GHG reduction targets by 2025. As of end 2024, 65% had committed, exceeding the target. Pfizer engages suppliers through annual supplier summits, the Energize (renewable energy PPA education) and Activate (API supply chain decarbonisation) programs, a training academy, and contract requirements mandating science-based targets. Over 309 suppliers registered for Energize; 39 Pfizer supplier organizations representing 68 facilities participate in Activate.

sustainability_report p.124

Pfizer targets a 10% reduction in upstream transportation and distribution (Scope 3 Cat 4) emissions by 2025 vs 2019. As of end 2024, Cat 4 emissions were 23% below the 2019 baseline. In 2024, Pfizer shifted shipments from air to ocean where feasible, adopted biofuels in select transport lanes with certified emissions factors, piloted electric medium-duty freight vehicles in regions with supporting infrastructure, and advanced circularity initiatives to reduce waste and emissions. Pfizer uses the GLEC Framework for emissions calculations and applies low emissions fuels certificates provided by logistics suppliers.

sustainability_report p.103

Pfizer's Sustainable Medicines Program drives process innovation to reduce GHG impacts across the product lifecycle. Pfizer has conducted over 20 life cycle assessments (LCAs) across small molecules, biologics, vaccines, and devices to identify emissions hotspots. These insights inform manufacturing improvements and product design decisions. Pfizer is a founding member of the Pharmaceutical Life-Cycle Assessment (Pharma LCA) Consortium, working toward a sector-wide LCA standard. The green chemistry innovation Enviero® progesterone uses a plant sterols pathway reducing manufacturing GHG by approximately 72% (184 kg CO2e per kg vs 256 kg CO2e per kg for the original route).

sustainability_report p.106

Pfizer's vehicle fleet — primarily commercial sales reps engaging with healthcare providers — accounted for ~12% of Scope 1 emissions in 2024. Pfizer is transitioning to battery electric vehicles (BEVs) where feasible, plus other low-emission options, and supports fuel management/efficient driving for ICE vehicles until retirement. BEVs are on the road in 10 markets with plans for additional markets in 2025 and beyond. Fleet and site upgrades combined are projected to reduce Scope 1 by 20-25%.

sustainability_report p.50

Pfizer's manufacturing site in Karachi, Pakistan was sold to Lucky Core Industries (LCI) in 2024.

sustainability_report p.135

Pfizer's manufacturing sites account for ~70% of company energy consumption and Scope 1+2 emissions. In 2024 Pfizer invested ~$31M (OPEX $6.2M + CAPEX $24.8M) in 232 emission-reduction projects across 32 sites, projected to reduce emissions by ~30,500 tCO2e annually and save ~$7.7M/year. Key 2024 projects: HVAC upgrades at Andover (MA), Kalamazoo (MI), Rocky Mount (NC); chiller/compressed-air improvements in Kalamazoo; boiler conversion from diesel to natural gas in Vizag, India. Sites maintain Net-Zero master plans and 2025-2030 pipeline of 340+ additional projects requiring $190M+ incremental investment.

sustainability_report p.53

Pfizer's focus is driving absolute GHG reductions in line with Net-Zero by 2040. The firm anticipates a carbon removal strategy may be necessary to address hard-to-abate residual emissions as it approaches the target end date. Pfizer explicitly states it does not plan to mitigate emissions beyond its value chain and does not intend to purchase carbon credits for neutralization or beyond-value-chain mitigation. No project-based carbon credits were retired in the reporting year.

sustainability_report p.341

Pfizer conducts robust TCFD-aligned risk assessments and discloses a climate transition plan aligned with 1.5°C world. Scenario analysis uses RCP 2.6, RCP 8.5, NGFS Net-Zero 2050, and NGFS Current Policies pathways.

sustainability_report p.101

Pfizer is a member of RE100 and has committed to achieve 100% renewable electricity by 2030. Pfizer invests in no- and low-carbon technologies at sites and through Virtual Power Purchase Agreements (VPPAs) that enable sourcing of renewable energy. VPPAs covering solar projects in Spain and the United States, coming online in 2025, are expected to generate RECs to cover approximately 100% of Pfizer's purchased electricity needs in North America and the EU. Pfizer also has on-site solar at multiple facilities globally and purchases renewable electricity via retail supply contracts backed by Guarantees of Origin (GOs) and IRECs in several countries. As of 2024, 14.4% of total electricity was from renewable sources. Pfizer is working to advance country-specific projects to cover electricity consumption outside of North America and Europe.

sustainability_report p.305

Due to business plans announced in May 2024 (Form 8-K) including the Seagen integration impacting GHG inventory/baseline, Pfizer paused its Science Based Targets initiative validation application. SBTi has reflected Pfizer's net-zero status as 'Commitment Removed.' Pfizer states no changes to net-zero ambitions and that near-term SBTi target remains validated.

sustainability_report p.30

Pfizer is an RE100 member committed to 100% renewable electricity by 2030. Virtual Power Purchase Agreements (VPPAs) covering solar projects in Spain and the United States came online in 2025 and are expected to generate RECs covering approximately 100% of Pfizer's purchased electricity needs in North America and the EU. Pfizer is working to advance country-specific projects to cover electricity consumption outside North America and Europe. In 2024 renewable electricity reached 14.4% of total electricity (up from 9.5% in 2019). On-site solar installations across Belgium, India, Ireland, Italy, Singapore, Spain, US and other markets contributed additional generation.

sustainability_report p.305

Pfizer maps work to SDGs: Good Health and Well-Being (3), Gender Equality (5), Decent Work and Economic Growth (8), Industry/Innovation/Infrastructure (9), Reduced Inequalities (10), Responsible Consumption and Production (12), Climate Action (13), Peace/Justice/Strong Institutions (16), Partnerships for the Goals (17).

sustainability_report p.38

Pfizer's Water Stewardship Position Statement and climate policy commitments are explicitly aligned with Paris Agreement and UN Sustainable Development Goal 6 (Clean Water and Sanitation).

sustainability_report p.78

Ringaskiddy Clinical Manufacturing Facility (Cork, Ireland) and Madrid office received LEED Gold; Vienna office awarded Platinum status; New York HQ awarded both LEED Platinum and WELL Platinum certifications in 2024.

sustainability_report p.50

NY headquarters awarded both LEED Platinum and WELL Platinum certifications. Ringaskiddy (Cork, Ireland) clinical manufacturing facility and Madrid office received LEED Gold; Vienna office achieved Platinum.

sustainability_report p.31

Pfizer's Catania, Italy site received BSI Kitemark certification to the Antibiotic Manufacturing Standard for Drug Product. Ringaskiddy site certified for API for an antibiotic. One contract manufacturer also obtained Kitemark for both API and DP.

sustainability_report p.36

Pfizer developed approach to managing biodiversity risks in collaboration with World Wildlife Fund (WWF). Building on 2023 biodiversity risk assessments, now focusing on tracking and improving the relationship between Pfizer's physical sites and nature, including site-level plans for nature-positive outcomes.

sustainability_report p.36

Pfizer enhanced and updated baseline requirements for responsible water management focusing on responsible water use, minimizing environmental impacts from wastewater effluent, and groundwater/surface water protection. Completed detailed water risk assessments at sites based on 2023 water stress assessments.

sustainability_report p.36

Pfizer maintains a human rights diligence program focused on targeted high-risk areas identified by Global Slavery Index; integrates SA 8000 considerations into supplier evaluations. Modern Slavery Statement published.

sustainability_report p.25

Pfizer sourced 14% renewable electricity in 2024 (up from 10% in 2023). Key initiative is virtual power purchase agreements (VPPAs) covering solar projects in Spain and the United States, coming online in 2025, expected to generate RECs to cover approximately 100% of Pfizer's purchased electricity needs in North America and the EU. Targets: 80% renewable electricity by 2025, 100% by 2030. Pfizer is working to advance country-specific projects to cover electricity consumption outside of North America and Europe.

sustainability_report p.31

As a result of improvements in methodology accounting for logistics and tertiary packaging material weights, Pfizer recalculated historical Category 4 emissions, including the 2019 baseline.

sustainability_report p.53

Pfizer is a founding member of the Pharmaceutical Life-Cycle Assessment (Pharma LCA) Consortium and has conducted 20+ LCAs across small molecules, large molecules, vaccines, and devices. Insights inform manufacturing process improvements and product design. Example outcome: Enviero® progesterone synthesized via plant sterols pathway, reducing GHG impact ~72% (from ~256 to ~72 kg CO2e per kg progesterone) vs. legacy chemical synthesis route.

sustainability_report p.345

Pfizer targets 25% reduction in Scope 3 Cat 6 business travel by 2025 vs. 2019; as of 2024, travel emissions were 55% below 2019 baseline (well ahead of target). Approach includes embedding sustainable travel messaging in booking tools, collaboration with preferred carriers aligned with GHG reduction goals, education on purposeful travel, and exploring policy revisions to further align travel with long-term emissions goals.

sustainability_report p.322

Pfizer aims to reduce Scope 3 Cat 4 upstream transportation 10% by 2025 vs. 2019; as of 2024, Cat 4 emissions were 23% lower than baseline. Tactics include: shifting shipments from air to ocean where feasible, adopting biofuels with certified emissions factors, piloting electric medium-duty freight in regions with supporting infrastructure, and developing an internal visualization tool that provides transparency on emissions per route by customer, lane, and mode.

sustainability_report p.318

Air travel emissions for all years, including the 2019 baseline, have been adjusted to include well-to-wheel (WTW) emissions. Estimates for travel booked outside Pfizer's travel system (~10% of total) included for all years.

sustainability_report p.53

Data for 2022-2024 Scope 1 & 2 emissions is independently verified to the reasonable assurance level by ERM CVS, up from limited assurance for the 2019 baseline.

sustainability_report p.53

Procurement of goods and services is the largest contributor to Pfizer's Scope 3 emissions (78% of Scope 3). Pfizer targets 64% of suppliers by spend to set science-based GHG reduction targets by 2025; as of end-2024, 65% had committed (vs. ~38% in 2023). Pfizer is engaging ~500 parent suppliers representing ~80% of Cat 1+2 emissions. Tools include: PSCI membership, annual Supplier Summit, Pfizer-sponsored training academy, Energize program (renewable PPA education via Schneider Electric — 309 suppliers registered), and Activate program (39 supplier organizations, 68 facilities participating in API decarbonization).

sustainability_report p.124

Pfizer's manufacturing site in Karachi, Pakistan was sold to Lucky Core Industries (LCI) in 2024, reducing Pfizer's operational emissions footprint. Divestment contributed 4,868 tCO2e decrease in S1+S2 vs prior year.

sustainability_report p.135

Emission factors for Scope 1&2 updated to latest releases. Refinements in how logistics and tertiary packaging material weights are accounted for in upstream transportation (Cat 4), reducing reported Cat 4 by ~16% for 2023. Inclusion of well-to-wheel (WTW) emissions for air travel in business travel (Cat 6), increasing 2023 Cat 6 by ~8%. Three remediation sites reclassified from Scope 1 to Scope 3 Cat 1.

sustainability_report p.136

Pfizer recalculated 2019 base year emissions for Scopes 1, 2 (location and market), and 3 to reflect updated emission factors, structural changes (Seagen acquisition), and methodology enhancements. Applied to all changes regardless of significance threshold.

sustainability_report p.136

Pfizer obtained reasonable assurance (ISAE3000) for Scope 1 and Scope 2 (both market-based and location-based) for 2024 data, with 100% of reported emissions verified by ERM CVS. Scope 3 categories 1-8 and 15 received limited assurance. Annual process, complete for 2024.

sustainability_report p.164

Pfizer's New York headquarters was awarded LEED Platinum and WELL Platinum certifications. Ringaskiddy Clinical Manufacturing Facility (Ireland) and Madrid office received LEED Gold; Vienna office received LEED Platinum. Demonstrates commitment to energy-efficient buildings.

sustainability_report p.50

Pfizer entered into Virtual Power Purchase Agreements (VPPAs) covering solar projects in Spain and the United States. These came online in first semester 2025 and are expected to generate RECs to cover approximately 100% of Pfizer's purchased electricity needs in North America and the EU.

sustainability_report p.50

Catania, Italy site earned BSI Kitemark quality certification to AMRIA Antibiotic Manufacturing Standard for drug product manufacturing; Ringaskiddy, Ireland received certification for API production. One contract manufacturer also achieved certification.

sustainability_report p.35

Pfizer obtained reasonable (high-bar) assurance from ERM CVS on Scope 1 and Scope 2 (both location and market-based) emissions and limited assurance on Scope 3 categories 1-8 and 15. ISAE 3000 standard.

sustainability_report p.164

Base year emissions were recalculated to reflect methodology updates including WTW air travel and logistics/packaging weight refinements. Scope 1, Scope 2 (location and market), and Scope 3 baselines were restated.

sustainability_report p.136

Three remediation sites previously classified under Pfizer's operational control reclassified as Scope 3 Cat 1: Purchased Goods and Services, reflecting third-party management under service contracts.

sustainability_report p.136

Pfizer intends to neutralize residual (hard-to-abate) emissions with permanent carbon removals at the end of its Net-Zero 2040 target period. The firm does not plan to purchase and cancel carbon credits for neutralization or beyond-value-chain mitigation currently. No carbon offsets or project-based credits were retired in the 2024 reporting year. Pfizer acknowledges that a carbon removal strategy may be necessary as it progresses toward 2040 target end dates, but specific removal mechanisms (e.g., DAC, BECCS) have not been publicly committed to in this disclosure.

sustainability_report p.341

Pfizer's Environmental Impact Reduction Standard requires all sites to develop systematic energy conservation plans. In 2024, Pfizer completed over 230 emission reduction projects at 32 sites globally, investing approximately $31M (OPEX $6.2M + CAPEX $24.8M) to reduce emissions by nearly 30,500 tCO2e annually. Key projects include HVAC upgrades at Andover, Kalamazoo, and Rocky Mount; chiller and compressed air improvements in Kalamazoo; and a boiler conversion from diesel to natural gas in Vizag, India. Projected annual cost savings of approximately $7.7M. Sites with medium-to-large energy use maintain sustainability master plans and set internal annual targets.

sustainability_report p.53

Pfizer's fleet of vehicles, used primarily by commercial teams for healthcare provider engagement, accounted for approximately 12% of total Scope 1 GHG emissions in 2024. Pfizer is working to transition its fleet to battery electric vehicles (BEVs) and other low-emission vehicle options. BEVs are on the road in 10 markets with plans for additional markets in 2025 and beyond. Pfizer is also supporting fuel management and efficient driving choices for internal combustion vehicles until they can be retired. Fleet and site upgrades are projected to reduce Scope 1 emissions by 20-25% toward the 2030 target.

sustainability_report p.50

Pfizer set an SBTi-validated target to reduce business travel emissions 25% by 2025 vs 2019. As of end 2024, travel-related GHG emissions were 55% lower than the 2019 baseline, significantly exceeding the target. Pfizer has embedded sustainable travel messaging in booking tools, uses digital platforms to limit travel, and collaborates with preferred carriers aligned with GHG reduction goals. Air, car, and rail emissions include well-to-wheel (WTW) factors. Pfizer is exploring internal policy revisions to further align travel with long-term emissions reduction goals.

sustainability_report p.103

Pfizer acquired Seagen Inc. in December 2023. Unless otherwise noted, KPIs in this report exclude data from Seagen. Future periods will integrate Seagen data, which will affect year-over-year comparability of nearly all metrics.

sustainability_report p.2

Pfizer aims to achieve the SBTi voluntary Net Zero standard by 2040, 10 years ahead of the standard's timeline. Commitment: 95% reduction in operational GHG and 90% in value-chain emissions from 2019 levels by 2040.

sustainability_report p.39

Pfizer's near-term SBTi-validated target: reduce Scope 1 and 2 GHG emissions by 46% from 2019 baseline by 2030, aligned with a 1.5°C trajectory, inclusive of 100% renewable electricity target.

sustainability_report p.3

Pfizer is an RE100 member and targets 80% renewable electricity by 2025 and 100% by 2030, supported by virtual power purchase agreements (VPPAs) in North America and the EU.

sustainability_report p.38

Pfizer's 2025 goal: achieve a 25% reduction in business travel emissions from the 2019 baseline (288 thousand tCO2e target).

sustainability_report p.3

Scope 3 supplier engagement goal: 64% of suppliers by spend committed to science-based GHG targets by 2025. Tracking began in 2021 (19%). Progress: 19% (2021) → 29% (2022) → 51% (2023).

sustainability_report p.3

In 2023, Pfizer aligned upstream transportation and distribution emissions methodology with the Global Logistics Emissions Council (GLEC) framework and expanded use of primary activity data. Methodology applied retroactively to historical estimates.

sustainability_report p.3

Pfizer added estimates to 2019-2023 business travel results to account for travel booked outside Pfizer's travel system (~10% of total business travel emissions). Improves completeness of disclosure.

sustainability_report p.3

Pfizer is conducting representative LCAs for small molecules, large molecules, vaccines, and devices to identify highest-impact reduction opportunities, and is developing sustainable product-design principles across R&D. Participating in a consortium with NHS England to develop a sector-wide LCA standard for pharmaceuticals.

sustainability_report p.39

Pfizer aligns its reporting with multiple UN Sustainable Development Goals across the GRI Index: SDG 3 (Good Health), 5 (Gender Equality), 8 (Decent Work), 9 (Industry & Innovation), 10 (Reduced Inequalities), 12 (Responsible Consumption), 13 (Climate Action), 16 (Peace, Justice, Strong Institutions), 17 (Partnerships).

sustainability_report p.12

In July 2023, Pfizer's Rocky Mount, NC manufacturing facility was impacted by a tornado. Most damage was to the warehouse storing raw materials, packaging and finished medicines awaiting QA release. Cited as a physical climate-risk event by Pfizer's TCFD report.

sustainability_report p.38

Pfizer's annual performance-based variable bonus program includes a climate-performance KPI as part of an ESG modifier, linking executive compensation to GHG emissions reduction progress.

sustainability_report p.34

Pfizer's 2040 Net Zero strategy is framed around 95% operational and 90% value-chain emissions reductions from a 2019 baseline, with no explicit reliance on carbon removals (DAC, BECCS, biochar, nature-based) disclosed in this report. The remaining residual emissions strategy is not detailed; Pfizer emphasises absolute reductions and supplier decarbonisation over offset/removal procurement.

sustainability_report p.39

Manufacturing at Pfizer's internal sites (PGS) accounts for >70% of energy consumption and GHG emissions. Sites maintain master plans identifying emission-reduction opportunities; capex projects are reviewed via the capital appropriation process. Investments include replacing end-of-life equipment with energy-efficient alternatives and shifting from gas to electric heating to reduce exposure to fuel-price volatility.

sustainability_report p.38

2025 target: 25% reduction in business travel emissions from 2019 baseline (384 thousand tCO2e). 2023 emissions of 173 thousand tCO2e remain well below the 2019 baseline but are rebounding sharply post-COVID (39 in 2021 → 94 in 2022 → 173 in 2023). Pfizer added estimates for off-system travel (~10%) to improve completeness.

sustainability_report p.3

Scope 3 represents ~80% of Pfizer's emissions. Strategy: embed environmental criteria in vendor selection, strengthen contract expectations, and engage key suppliers to set SBTi-validated GHG goals. Progress: 19% (2021) → 51% (2023) of suppliers by spend with science-based targets; goal 64% by 2025.

sustainability_report p.3

Pfizer completed the acquisition of Seagen in December 2023. Emissions associated with Seagen's operations have been incorporated into Pfizer's footprint, contributing to higher Scope 3 emissions in 2024 reporting.

sustainability_report p.135

Pfizer is a member of RE100 and has entered virtual power purchase agreements (VPPAs) for solar-generated renewable electricity in North America and the European Union that will effectively cover all of Pfizer's purchased electricity in those jurisdictions. Interim goal: 80% renewable electricity by 2025; 100% by 2030. Renewable electricity reached 10% in 2023 (vs 7% in 2022), indicating most of the planned step-up is back-loaded as VPPAs come online.

sustainability_report p.38

Pfizer completed acquisition of Seagen in December 2023. Seagen's emissions have been incorporated into Pfizer's GHG footprint going forward.

sustainability_report p.135

Pfizer participates in Energize, a cross-pharma collaboration giving suppliers access to renewable-electricity PPA markets they could not otherwise reach. Also a member of Activate, a collective-action initiative supporting decarbonisation of active pharmaceutical ingredient (API) supply chains.

sustainability_report p.39

Upstream transport emissions trended up from 249 ktCO2e (2019) to 440 (2022) before dropping to 305 in 2023, partly driven by methodology realignment with the GLEC framework and increased use of primary activity data. 2025 goal: 224 ktCO2e (10% below baseline).

sustainability_report p.3

Pfizer acquired Seagen in 2023 and integrated operations during 2024. The acquisition expanded Oncology organization and affected GHG inventory/baseline considerations.

sustainability_report p.15

While Pfizer's primary focus is driving absolute GHG reductions across its value chain to achieve net-zero by 2040, the company anticipates that a carbon removal strategy may be necessary to address hard-to-abate emissions as it progresses towards the target end dates. Pfizer has stated it intends to neutralise unabated emissions with permanent carbon removals at the target year but has not yet specified removal technology or volumes. No carbon removals, offsets or credits were retired in the reporting year.

sustainability_report p.59

In 2022, Pfizer announced aim to achieve the voluntary Net Zero Standard by 2040, ten years earlier than the standard's timeline. Targets: 46% Scope 1+2 reduction by 2030; 95% Scope 1+2 reduction by 2040; 90% value chain reduction by 2040; 100% renewable electricity by 2030 (80% by 2025).

sustainability_report p.30

2019 GHG data verified to limited assurance level by ERM-CVS; 2021-2022 data upgraded to reasonable assurance. Verification of 2023 data in progress at time of report publication.

sustainability_report p.3

Pfizer set Abs 6: 95% reduction in Scope 1+2 emissions by 2040 from 2019 baseline, aligned with Net-Zero Standard. As of end 2024, 15.63% achieved (15% reduction from baseline).

sustainability_report p.324

Pfizer set Abs 7: 90% absolute reduction in Scope 3 emissions (all relevant categories) by 2040 from 2019 baseline. As of end 2024, -15.61% achieved (Scope 3 increased from base year due to Seagen acquisition and methodology changes).

sustainability_report p.327

Pfizer committed to achieving the voluntary Net-Zero Standard by 2040, ten years earlier than the standard's timeline, covering Scopes 1, 2, and 3. Target covers at least 95% of S1+S2 and at least 90% of S3. Intends to neutralize residual emissions with permanent carbon removals.

sustainability_report p.339

In June 2022, Pfizer CEO committed to accelerate decarbonization of value chain, aiming to achieve SBTi voluntary Net-Zero Standard by 2040, including 90% absolute reduction in value chain emissions from 2019 baseline. Submission to SBTi planned for 2023.

sustainability_report p.5

Expanded boundary for Scope 3 Business Travel to include use of personal vehicles for business by US Fleet colleagues, applied retroactively to 2019-2022.

sustainability_report p.64

Revised methodology for calculating Scope 3 Upstream Transportation & Distribution emissions to more accurately capture source data; applied to 2019-2022 calculations.

sustainability_report p.64

Pfizer's reporting boundary was baseline-adjusted per GHG Protocol to reflect acquisitions (San Diego, San Francisco R&D sites), divestitures (Adelaide, Australia; Valencia, Venezuela), and site closures.

sustainability_report p.65

Reasonable assurance applied to Scope 1 and Scope 2 (both location and market) emissions; limited assurance for Scope 3 categories per ISAE3000 by ERM CVS.

sustainability_report p.128

New API manufacturing facility in Tuas, Singapore issued Green Mark Gold Certificate by Singapore Building and Construction Authority in December 2022.

sustainability_report p.33

Pfizer's environmental sustainability approach supports Sustainable Development Goals 9, 12, and 13 (sustainable infrastructure & innovation; sustainable life cycle management; climate action).

sustainability_report p.147

Pfizer's Valencia, Venezuela manufacturing site was acquired by Calox International in October 2022; removed from footprint.

sustainability_report p.63

Acquired R&D laboratories in San Diego (March 2022, from Arena) and San Francisco (October 2022, from Global Blood Therapeutics).

sustainability_report p.63

Pfizer is a member of RE100 with a goal of 80% renewable electricity by 2025 and 100% by 2030. In 2021 entered a 15-year virtual PPA with Vesper Energy for ≥310 MW from the Hornet Solar project in west Texas (expected operational by Dec 2024), which will cover ~60% of global electricity needs through RECs. Pursuing additional VPPA in Europe and supplemental REC purchases. On-site solar generation at sites in US, Singapore, Belgium, Italy, India, Germany, Ireland, Morocco. 2022 renewable electricity share: 6.9%.

sustainability_report p.57

Pfizer's focus is on driving absolute GHG reductions, but anticipates a carbon removal strategy may be necessary to address hard-to-abate emissions as it progresses toward Net-Zero by 2040. No specific removal volumes, technologies (DAC/BECCS/nature-based), or vintage policy disclosed yet. Pfizer did not cancel any project-based carbon credits in the reporting year.

sustainability_report p.59

New Hudson Yards (NYC) headquarters designed to LEED v4 Gold and WELL v2 Gold; forecasts ~70% GHG reduction vs 2019 HQ. New Tuas Singapore API facility earned Green Mark Gold (Dec 2022). Kalamazoo modular aseptic processing facility targeting LEED Gold by 2024. Funded by $1.25B sustainability bond issued in 2020 ($946M allocated as of Dec 2022).

sustainability_report p.33

Pfizer implemented digital collaboration tools to reduce business travel and help colleagues choose lower-emission options when travel is necessary. 2022 business travel emissions were 78% below 2019 baseline, partly due to pandemic restrictions. SBTi-validated target to reduce 25% from 2019 by 2025.

sustainability_report p.55

Upstream transport is ~7% of Scope 3. SBTi-approved target to reduce 10% by 2025 from 2019 baseline. In 2022 emissions increased due to continued COVID-19 vaccine cold-chain air distribution, but Pfizer transitioned other product shipments from air to ocean and is partnering with logistics suppliers on biofuel options.

sustainability_report p.48

LCAs show 70-90% of small-molecule product carbon footprint is from API manufacture, with organic solvents the largest contributor. Pfizer applies green chemistry, solvent recycling/reuse, and process step reduction. Example: Enviero® progesterone now synthesized via plant sterols pathway, reducing carbon footprint ~72% (184 kg CO2e/kg API saved vs original route).

sustainability_report p.62

In June 2022, Pfizer announced ambition to achieve the voluntary SBTi Net-Zero Standard by 2040 (10 years earlier than the standard timeline), aiming to reduce company GHG by 95% and value chain GHG by 90% from 2019 levels.

sustainability_report p.22

Reducing Scope 1 & 2 GHG emissions by 46% from 2019 baseline by 2030; sourcing 80% renewable electricity by 2025 and 100% by 2030; reducing upstream transport emissions 10% and business travel 25% by 2025 from 2019; driving 64% of suppliers by spend to set science-based targets by 2025.

sustainability_report p.22

Pfizer reports alignment with SDGs 3 (Good Health), 5 (Gender Equality), 8 (Decent Work), 9 (Industry/Innovation), 10 (Reduced Inequalities), 12 (Responsible Consumption), 13 (Climate Action), 16 (Peace/Justice), and 17 (Partnerships).

sustainability_report p.21

Recognized at the Leadership Level for CDP Climate Change Disclosure.

sustainability_report p.7

Pfizer completed the acquisition of Global Blood Therapeutics, Inc., a biopharmaceutical company focused on sickle cell disease treatments.

sustainability_report p.29

Pfizer revised methodology for calculating upstream transportation emissions to more accurately capture source data; applied to 2022 calculations. Prior years under review.

sustainability_report p.50

In 2022 Pfizer published a Water Stewardship position statement and completed water risk assessments at all Pfizer sites; action plans to be developed in 2023 for elevated-risk sites.

sustainability_report p.25

Pfizer launched An Accord for a Healthier World in May 2022, providing on a not-for-profit basis innovative medicines and vaccines to 1.2 billion people in 45 lower-income countries. Expanded in January 2023 to ~500 patented and off-patent products.

sustainability_report p.16

Aspire to achieve 47% women at VP+ globally and 32% US minorities at VP+ by 2025; double underrepresented African American/Black and Hispanic/Latino representation.

sustainability_report p.35

2019-2021 GHG data (including Scope 3 categories 1-8 and 15) independently assured to limited assurance level by ERM-CVS per ISAE 3000. 2022 verification in progress.

sustainability_report p.80

Pfizer recognizes interconnectedness of climate, nature and biodiversity. Site-level nature-based solutions include Itapevi (Brazil) project that inventoried 2,000+ native trees acting as habitat and carbon sink. No DAC/BECCS/durable removals program disclosed; net-zero strategy focused on 95% absolute reduction in company emissions and 90% in value chain by 2040 rather than offsets or removals.

sustainability_report p.25

Manufacturing and R&D sites (>70% of company energy use) have environmental sustainability plans. Pfizer invests in no/low-carbon technologies, replaces end-of-life equipment with energy-efficient alternatives, and pursues process enhancements to reduce process steps and resource demand. Site master plans identify emission reduction opportunities reviewed via capital project appropriation process.

sustainability_report p.23

Target to reduce business travel GHG emissions by 25% from 2019 baseline by 2025. 2022 travel emissions of 80.2 ktCO2e were 78% lower than 2019 baseline (359.5 ktCO2e). Will continue utilizing digital tools to limit travel.

sustainability_report p.22

Target to reduce upstream transport emissions 10% from 2019 baseline by 2025. PAXLOVID and COVID-19 vaccine cold-chain air transport drove increases, but Pfizer eliminated ~50,000 mt CO2e in 2022 by shifting other shipments from air to ocean.

sustainability_report p.22

Long history of green chemistry. Developing sustainable product design principles across modalities. Conducting representative life cycle assessments (LCAs) for small molecules, large molecules, vaccines and devices to identify GHG reduction focus areas in development and manufacturing.

sustainability_report p.24

In June 2022, Pfizer announced its aim to achieve the voluntary Net-Zero Standard by 2040, ten years earlier than the SBTi Net-Zero Standard timeline. Aim to reduce company GHG emissions by 95% and value chain emissions by 90% from 2019 levels.

sustainability_report p.22

Near-term SBTi-approved targets: reduce Scope 1&2 by 46% by 2030 from 2019 baseline; 80% renewable electricity by 2025, 100% by 2030; 64% of suppliers by spend setting SBTs by 2025; 10% reduction in upstream transport and 25% reduction in business travel by 2025.

sustainability_report p.22

Pfizer revised methodology for upstream transportation emissions to more accurately capture source data and applied this methodology to 2022 calculations; previous years' data is in review.

sustainability_report p.50

Pfizer aligns ESG approach with UN Sustainable Development Goals: Good Health (3), Gender Equality (5), Decent Work (8), Industry/Innovation (9), Reduced Inequalities (10), Responsible Consumption (12), Climate Action (13), Peace/Justice (16), and Partnerships (17).

sustainability_report p.21

Pfizer completed the acquisition of Global Blood Therapeutics, Inc., a biopharmaceutical company focused on sickle cell disease and other underserved patient communities.

sustainability_report p.29

In 2022, Pfizer published a Water Stewardship position statement and completed water risk assessments at all Pfizer sites. Plans to develop site-level action plans in 2023 for sites with elevated risk scores.

sustainability_report p.25

In May 2022, Pfizer launched An Accord for a Healthier World to provide on a not-for-profit basis its full portfolio (~500 patented and off-patent products by Jan 2023) to 1.2 billion people in 45 lower-income countries.

sustainability_report p.16

By 2025, aim to achieve global workforce parity of 47% for women at VP+ level and 32% for US minorities at VP+ level, and double underrepresented populations of African Americans/Blacks and Hispanics/Latinos.

sustainability_report p.35

2019-2021 GHG data was independently verified to limited assurance level by ERM-CVS; verification of 2022 data was to be completed in 2023 (not yet assured at time of report).

sustainability_report p.50

Pfizer is a member of RE100 and targets 80% renewable electricity by 2025 and 100% by 2030. In 2021 it entered a 15-year virtual PPA with Vesper Energy for at least 310 MW from the Hornet Solar project in west Texas (expected operational by Dec 2024), expected to cover North American purchased electricity needs (~50% of global use). In 2022 Pfizer also pursued a European virtual PPA. 2022 renewable electricity was 7.8%.

sustainability_report p.23

Pfizer recognizes interconnectedness of climate, natural systems and biodiversity but does not disclose a durable removals (DAC/BECCS) portfolio. Site-level nature-based projects include the Itapevi, Brazil site where 2,000+ native trees were inventoried and biodiversity is being doubled, acting as a carbon sink. The Net-Zero strategy emphasizes deep emission reductions (95% company, 90% value chain) rather than reliance on offsets/removals.

sustainability_report p.25

Manufacturing and R&D sites have environmental sustainability plans to reduce energy consumption, water and waste. Pfizer replaces equipment at end-of-life with energy-efficient alternates, invests in no/low-carbon technologies, and undertakes process enhancements to reduce steps and resources. PGS accounts for >70% of Pfizer's energy use and GHG emissions and is the executive sponsor of climate risk management.

sustainability_report p.23

Scope 3 is ~80% of Pfizer's footprint; procurement of goods and services is the most significant contributor. Target: drive 64% of suppliers by spend to set SBTi-validated GHG reduction goals by 2025; reached 29% in 2022 (up from 19% in 2021). Pfizer integrates environmental criteria in sourcing/contracting and participates in collective initiatives including Energize (PPA access for suppliers) and Activate (API supply-chain decarbonization with peer pharma companies).

sustainability_report p.23

Although emissions from cold-chain air transport of PAXLOVID and COVID-19 vaccine continued to grow, Pfizer eliminated approximately 50,000 mt of GHG emissions in 2022 by transitioning other product shipments from air to ocean. Target is 10% reduction in upstream transport emissions by 2025 from 2019 baseline.

sustainability_report p.22

Pfizer is developing sustainable product design principles across modalities to systematically conserve energy, reduce water/raw materials, drive out waste, and embrace circular solutions. Representative life-cycle assessments (LCAs) for small molecules, large molecules, vaccines, and devices are used to identify GHG reduction opportunities in development and manufacturing.

sustainability_report p.24

CEO committed in June 2022 to accelerate decarbonisation of Pfizer's value chain, aiming to achieve SBTi's voluntary Net-Zero Standard by 2040 with 90% absolute value chain reduction from 2019 baseline. SBTi validation to be sought in 2023. Unabated residual emissions to be addressed with permanent carbon removals.

sustainability_report p.5

Pfizer revised its methodology for calculating Scope 3 Upstream Transportation & Distribution to more accurately capture source data and applied this methodology retroactively to 2019-2022 calculations, resulting in a restated base year figure.

sustainability_report p.64

Pfizer acquired ~125,000 sq ft R&D lab in San Diego from Arena Pharmaceuticals (March 2022) and ~164,000 sq ft R&D site in San Francisco from Global Blood Therapeutics (October 2022), adding these to the GHG reporting boundary.

sustainability_report p.63

In February 2022, Pfizer's Compensation Committee approved addition of an ESG modifier (including a GHG emissions reduction target) to the annual performance-based variable bonus program, applicable to the CEO, Executive Leadership Team and ~50% of colleagues.

sustainability_report p.7

Pfizer expanded the boundary for Scope 3 Business Travel to include use of personal vehicles for business by US Fleet colleagues and updated calculations for baseline year (2019) and subsequent years 2019-2022.

sustainability_report p.64

Pfizer's reporting boundary was baseline-adjusted per the GHG Protocol to reflect the Adelaide (Australia) and Valencia (Venezuela) divestitures, new R&D lab acquisitions, and site closures. All scopes (1, 2 location, 2 market, 3) were recalculated.

sustainability_report p.65

Pfizer integrates environmental sustainability into all capital projects. The new Tuas, Singapore API manufacturing facility received a Green Mark Gold Certificate (December 2022) and incorporates heat recovery from chillers and air compressors. The new Hudson Yards, New York headquarters is targeting LEED Gold and WELL v2 certification with a forecast ~70% GHG reduction vs 2019 headquarters. The Kalamazoo, Michigan aseptic processing facility is on track for LEED Gold by 2024. An internal carbon shadow price of $20/tCO2e is applied to capital expenditure decisions to encourage low-carbon design choices.

sustainability_report p.33

Business travel (Cat 6) represented ~6% of Pfizer's Scope 3 footprint in the 2019 base year (359,523 tCO2e). In 2022 travel emissions were 80,167 tCO2e — 78% below baseline, substantially aided by pandemic-related restrictions. Pfizer has implemented digital tools to reduce the need for travel and, where travel is necessary, helps employees choose lower-emission transport options. A 25% absolute reduction from the 2019 base by 2025 has been set as an SBTi-validated target. Travel booked outside Pfizer's system (9-13% of air, 35-45% hotel, 15-22% car) is estimated to add >5% to reported totals.

sustainability_report p.55

Pfizer's Valencia, Venezuela manufacturing site was divested to Calox International in October 2022 and removed from Pfizer's footprint as part of the 2022 baseline adjustment process. Adelaide, Australia site (divested to Bridgewest Group in 2020) also removed.

sustainability_report p.63

Pfizer became a member of RE100 in January 2022, committing to achieve 100% renewable electricity by 2030 (80% by 2025), consistent with its Scope 1+2 near-term SBTi target.

sustainability_report p.148

Purchased goods and services represent 85% of Pfizer's total Scope 3 footprint (~$8.2 Mt CO2e in 2022). Pfizer has integrated environmental criteria into supplier sourcing, contracting and performance management, requiring ~200 key suppliers (10% by number, 64% by spend) to establish SBTi-aligned Scope 1+2 GHG targets by 2025. At end of 2022, 29% of procurement spend had obtained or committed to SBTi targets. Pfizer also co-founded the Energize programme with 10 pharma peers (delivered by Schneider Electric) to help pharmaceutical suppliers access renewable energy PPAs and EACs, and joined the Activate initiative in November 2022 to decarbonise API supply chains including CMOs.

sustainability_report p.135

70-90% of the carbon footprint of Pfizer's small molecule products is associated with manufacture of active pharmaceutical ingredients (API), with organic solvents the single largest contributor. Pfizer conducts life cycle assessments across small molecule, large molecule, vaccine and device portfolios to define environmental sustainability criteria throughout the product lifecycle. Green chemistry innovation (e.g. the Enviero progesterone plant-sterols pathway reducing API carbon footprint by 72%) and solvent recycling and reuse programmes are being advanced. Pfizer also joined the Activate initiative in 2022 to drive GHG reductions at API suppliers and CMOs.

sustainability_report p.31

Upstream transportation and distribution (Cat 4) is Pfizer's second largest Scope 3 category at 712,318 tCO2e in 2022 (vs 611,059 tCO2e 2019 base), representing ~7% of total Scope 3. Increased emissions in 2022 were driven by continued global COVID-19 vaccine distribution predominantly by air using cold-chain technologies. Pfizer actively reduced emissions by transitioning other product shipments from air to ocean and is partnering with logistics suppliers to identify further reductions including potential use of biofuels. A 10% reduction target vs 2019 by 2025 was set and validated by SBTi.

sustainability_report p.48

Pfizer's manufacturing and R&D sites (Pfizer Global Supply) account for ~75% of company energy consumption and Scope 1+2 emissions. In 2022, Pfizer invested $26M to implement 103 energy-efficiency projects at 31 sites in Europe, Asia, India and the US, reducing emissions by ~21,000 tCO2e annually and saving ~$6M per year. Projects included HVAC optimisation (50% of savings), chiller replacement/optimisation (19%), and boiler, compressed air, steam and lighting improvements. Medium and large sites are required to maintain sustainability master plans identifying prioritised emission reduction opportunities reviewed quarterly by senior leadership.

sustainability_report p.22

Pfizer is a member of RE100 and targets 80% renewable electricity by 2025 and 100% by 2030. In 2021 Pfizer entered into a 15-year virtual PPA with Vesper Energy for at least 310 MW of solar power from the Hornet Solar project in west Texas (expected operational by end 2024), which will cover ~60% of global electricity use. In 2022, Pfizer also purchased renewable electricity in Ireland, Austria, Croatia, Spain, Sweden, UK and Switzerland via retail green contracts, and generated solar/wind/geothermal electricity on-site in Belgium, Italy, Germany, Morocco, India and Singapore. Renewable electricity share was 6.9% in 2022; efforts to secure European PPAs and RECs are ongoing.

sustainability_report p.57

Pfizer Global Supply (manufacturing) accounts for ~75% of company's energy consumption and Scope 1+2 emissions. In 2022 invested $26M to implement 102 emission reduction projects at 31 manufacturing sites in Europe, Asia, India and US, reducing emissions ~20,912 tCO2e annually. ~50% of savings from HVAC optimization/replacement, ~20% from chiller replacements, remainder from boiler, compressed air, steam, lighting upgrades.

sustainability_report p.60

Purchased goods and services represent ~85% of Scope 3 emissions. Pfizer's SBTi-approved supplier engagement target requires 64% of suppliers by spend to set science-based targets by 2025. At end of 2022, 29% of suppliers by spend had SBTi-approved targets or commitments (up from 5% in 2019). Integrated environmental criteria into supplier sourcing, contracting, performance management. Co-founded Energize program for renewable energy procurement and Activate for API supply chain decarbonization.

sustainability_report p.58

Pfizer is RE100 member with goals of 80% renewable electricity by 2025 and 100% by 2030. In 2021 entered a 15-year virtual PPA with Vesper Energy for at least 310MW from the Hornet Solar project in west Texas (operational by Dec 2024), expected to cover Pfizer's North American purchased electricity needs (~50% of global electricity). Continuing efforts to establish a virtual PPA in Europe and secure additional RECs/PPAs. 2022 actual renewable electricity was 7.8%.

sustainability_report p.23

Scope 3 (value chain) GHG footprint is ~4x direct operations; procurement of goods/services is largest scope 3 contributor. Pfizer integrated environmental criteria into supplier sourcing, contracting, performance management. Target 64% of suppliers by spend to set SBTi targets by 2025 (29% as of 2022, up from 19% in 2021). Joined Activate initiative for API supply chain decarbonization. CDP Supplier Engagement Leader 2018-2021.

sustainability_report p.23

In June 2022, Pfizer's CEO committed to achieve the voluntary Net-Zero Standard by 2040 — 95% reduction in Scope 1+2 and 90% reduction in Scope 3 emissions from 2019 baseline. This is 10 years earlier than the timeline described in the SBTi Net-Zero Standard.

sustainability_report p.339

In early 2021 Pfizer concluded a three-year project to replace and remove six coal-fired boilers at the Kalamazoo, Michigan manufacturing site. Eliminates 10,800 mT CO2e of GHG emissions, 208 tons of non-GHG emissions, and 1,550 tons of coal ash annually.

sustainability_report p.26

Pfizer's fourth-generation GHG emission reduction targets were approved by the Science Based Targets initiative (SBTi) in February 2021 as aligned with a 1.5°C trajectory. Commitments: reduce Scope 1+2 by 46% from 2019 baseline by 2030; 80% renewable electricity by 2025 and 100% by 2030; reduce upstream transport by 10% and business travel by 25% by 2025; 64% of suppliers by spend to set SBT by 2025.

sustainability_report p.26

Pfizer aligns reporting and use-of-proceeds with UN Sustainable Development Goals: SDG 3 (Good Health), SDG 5 (Gender Equality), SDG 6 (Clean Water), SDG 7 (Affordable Clean Energy), SDG 8 (Decent Work), SDG 9 (Industry/Innovation/Infrastructure), SDG 10 (Reduced Inequalities), SDG 12 (Responsible Consumption), SDG 13 (Climate Action), SDG 16 (Peace, Justice), SDG 17 (Partnerships).

sustainability_report p.19

Pfizer recognized as CDP Supplier Engagement Leader for the fourth consecutive year for work to measure and reduce environmental risks in supply chain.

sustainability_report p.27

2021 was first year Pfizer reported upstream transportation & distribution carbon emissions (672.6 thousand tCO2e). COVID-19 vaccine transported predominantly by air using cold chain technologies drove an increase in logistics emissions.

sustainability_report p.53

In 2020 ESG report two metrics (Patients Treated 420+ million and Patients Reached 58+ million) were reported separately. In 2021 these were combined into a single KPI; 2020 was restated to 399 million patients treated under new methodology.

sustainability_report p.34

By 2025: achieve 47% women globally at VP+ level; achieve parity at VP+ for US minorities by increasing representation from 19% to 32% and doubling underrepresented African American/Black and Hispanic/Latino populations.

sustainability_report p.38

Effective 2022 performance year, Compensation Committee adopted ESG Scorecard for short-term incentive plan funding affecting 30,000+ colleagues. ESG metrics: women VP+ globally, US minorities VP+, and GHG emissions. Also included ESG KPI-linked metrics in $7B 5-year revolving credit facility.

sustainability_report p.49

Acquired Trillium Therapeutics Inc. (lead molecule TTI-622) in 2021 and announced acquisition of Arena Pharmaceuticals for immuno-inflammatory disease portfolio.

sustainability_report p.33

Pfizer committed to RE100 with 80% renewable electricity by 2025 and 100% by 2030. In October 2021 entered a 15-year virtual PPA with Vesper Energy for 310 MW of solar from the Hornet Solar project in west Texas starting 2023, effectively covering North American purchased electricity (~50% of global use). Working to establish a virtual PPA in Europe (~16% of global electricity) and securing RECs for the remainder by 2025. Sourced 6.5% renewable electricity in 2021.

sustainability_report p.27

Pfizer plans to address any residual emissions through 'high-quality and verifiable offsets' to achieve carbon neutrality across internal operations by 2030. The report does not specifically distinguish durable removals (DAC, BECCS) from avoidance credits; offsets framing is generic.

sustainability_report p.27

Manufacturing and R&D sites maintain long-term environmental sustainability masterplans covering energy efficiency, water, and waste. Pfizer invests $25-40 million per year on energy demand reduction via asset replacement, efficiency improvements and renewable installations, achieving ~$3-5M annual savings with 4-10 year paybacks. Manufacturing accounts for >70% of company energy and GHG.

sustainability_report p.78

Upstream transportation & distribution emissions reached 672.6 kt CO2e in 2021, driven by air-cold-chain transport of COVID-19 vaccines. Pfizer committed to a 10% reduction by 2025 from 2019 baseline; urgent shift from ocean to air for COVID products increased logistics emissions.

sustainability_report p.26

Sustainability Bond proceeds funding new multi-product API facility in Tuas, Singapore (energy-efficient design, comprehensive metering, completion 2023) and new corporate HQ at Hudson Yards NYC (targeting LEEDv4 Gold and WELLv2 Pilot Gold; 30% lighting power reduction below LEEDv4 baseline; low-flow plumbing). $401M of 2020 Sustainability Bond proceeds allocated to environmental projects through Dec 2021.

sustainability_report p.22

Life cycle assessments determined 70-90% of small-molecule product carbon footprint is API manufacturing; organic solvents are largest single contributor. Pfizer is conducting LCAs across small molecule, large molecule and device portfolios, applying green chemistry, solvent recycling and reuse. Kalamazoo, MI site recovered >50% of solvents used in 2021 through onsite distillation columns.

sustainability_report p.29

Pfizer's new Hudson Yards NYC corporate HQ and new Kalamazoo modular aseptic processing facility designed to achieve LEED Gold certification.

sustainability_report p.29

Pfizer joined the Business Ambition for 1.5C in 2021, signing the UN Global Compact Race to Zero commitment.

sustainability_report p.11

Business travel emissions were 92% below 2019 baseline in 2021 due to pandemic. Pfizer has implemented digital tools to reduce travel need and help colleagues choose lower-emission options. Target is 25% reduction from 2019 baseline by 2025 (SBTi 1.5°C aligned).

sustainability_report p.36

Pfizer's fourth-generation GHG emission reduction targets approved by Science Based Targets initiative (SBTi) as aligned with 1.5°C trajectory: 46% Scope 1+2 reduction from 2019 baseline by 2030; 100% renewable electricity by 2030 (80% by 2025); 25% business travel reduction; 10% upstream transport reduction; 64% of suppliers by spend to set science-based targets by 2025.

sustainability_report p.26

Pfizer committed to becoming carbon neutral across internal operations by 2030, with any residual emissions addressed through high-quality verifiable offsets.

sustainability_report p.26

Pfizer aligns its sustainability reporting with UN Sustainable Development Goals, particularly SDGs 3 (Good Health), 5 (Gender Equality), 6 (Clean Water), 7 (Affordable & Clean Energy), 8 (Decent Work), 9 (Industry, Innovation & Infrastructure), 10 (Reduced Inequalities), 12 (Responsible Consumption), 13 (Climate Action), 16 (Peace, Justice & Strong Institutions), and 17 (Partnerships). Sustainability Bond use-of-proceeds explicitly aligned to SDGs 3, 6, 7, 9, 12.

sustainability_report p.19

Transportation and distribution of Pfizer's COVID-19 vaccine, transported predominantly by air using cold chain technologies, contributed to an increase in upstream logistics emissions in 2021. Urgent need for COVID-19 treatments also prompted shift from ocean to air transportation.

sustainability_report p.26

Pfizer recognized as CDP Supplier Engagement Leader for the fourth consecutive year for measuring and reducing environmental risks in its supply chain.

sustainability_report p.27

In October 2021, Pfizer entered into a 15-year virtual PPA with Vesper Energy for 310 MW of renewable energy from the Hornet Solar project in west Texas, beginning 2023. Expected to effectively cover Pfizer's North American purchased electricity needs (~50% of global electricity).

sustainability_report p.27

By 2025, target 47% global workforce parity for women at VP+ level; achieve parity for U.S. minorities at VP+ by increasing representation from 19% to 32% and doubling African American/Black and Hispanic/Latino representation.

sustainability_report p.38

August 2021 Sustainability Bond raised $1.0 billion, supporting COVID-19 vaccine R&D and capital expenditures. Also established $7 billion 5-year revolving credit facility with ESG KPI-linked metrics (carbon emissions + DEI), the first U.S. biopharmaceutical company to do so.

sustainability_report p.18

Combined two previously separate metrics (Patients Treated 420M + Patients Reached 58M) into single 'Patients Treated' KPI. 2020 figure restated to 399 million under new methodology.

sustainability_report p.34

Pfizer sourced 6.5% renewable electricity in 2021 and signed a 15-year virtual PPA with Vesper Energy in October 2021 for 310 MW of solar from the Hornet Solar project in west Texas (beginning 2023), expected to effectively cover ~50% of global electricity needs (North America). Working to establish a virtual PPA in Europe (~16% of global electricity) and aim to secure RECs for the remaining purchased electricity by 2025. Committed to RE100; targeting 80% renewable electricity by 2025 and 100% by 2030.

sustainability_report p.27

Pfizer plans to address any residual emissions remaining after achieving the 46% absolute Scope 1+2 reduction by 2030 through 'high-quality and verifiable offsets'. The report does not distinguish between durable removals (DAC/BECCS/biochar) and avoidance credits, nor specify volumes, vintages, or certification standards. No carbon removal volumes were disclosed for 2021.

sustainability_report p.27

Manufacturing and R&D sites operate under long-term environmental sustainability masterplans to reduce energy consumption, water usage, and waste. Pfizer invests $25-40 million annually in emission reduction projects (asset replacement, efficiency improvements, on-site renewables), achieving ~$3-5M annual savings. Replacing equipment at end-of-life with energy-efficient alternatives and pursuing low-carbon technologies. Manufacturing accounts for >70% of energy consumption.

sustainability_report p.27

Business travel emissions fell 92% vs 2019 baseline due to pandemic restrictions (from 351.5kt to 29kt CO2e). Going forward, Pfizer commits to a 25% reduction from 2019 baseline by 2025, leveraging digital tools to permanently reduce travel.

sustainability_report p.26

Scope 3 is 4x Pfizer's direct operations, with purchased goods & services representing 66% of Scope 3 baseline. Pfizer is asking all suppliers to establish a GHG baseline by end of 2022 and set SBTi-aligned Scope 1+2 reduction targets by end of 2025. 10% of suppliers by spend had SBTi-approved targets in 2021; target is 64% by 2025. Joined 'Energize' (Schneider Electric-led pharma collaboration with 10 companies) to enable supplier renewable energy PPAs.

sustainability_report p.27

Upstream transportation & distribution accounted for 15% of Scope 3 baseline (672.6kt CO2e in 2019). Goal is 10% reduction by 2025 vs 2019 baseline. COVID-19 vaccine cold-chain air freight has driven upstream logistics emissions higher than baseline, presenting a near-term challenge.

sustainability_report p.26

70-90% of small-molecule product carbon footprint is from API manufacturing. Pfizer applies green chemistry, life cycle assessments, and solvent recycling. Example: new plant-sterol-based progesterone route generates 71.6 kg CO2e/kg vs 255.62 kg historical route (72% reduction, 184 kg CO2e/kg avoided).

sustainability_report p.27

ERM CVS provided reasonable assurance on Scope 1 and 2 emissions per ISAE3000. Scope 3 received limited assurance.

sustainability_report p.90

Scope 3 represents >80% of Pfizer's footprint with purchased goods & services the largest category (66% of Scope 3). Pfizer is asking suppliers to establish a GHG baseline by end of 2022 and set SBTi-aligned Scope 1+2 targets by end of 2025; goal of 64% of suppliers by spend with SBTs by 2025. 10% of suppliers by spend had SBTi-approved targets in 2021. Pfizer is part of the Energize collaboration (10 pharma companies, Schneider Electric) to enable supplier PPAs.

sustainability_report p.27

Pfizer committed to drive 64% of suppliers by spend to set their own science-based GHG reduction targets by 2025. Suppliers asked to establish GHG baseline by end of 2022 and SBTi-aligned targets by end of 2025. As of 2021, 10% of suppliers by spend had SBTi-approved targets. Environmental criteria embedded in supplier sourcing, contracting and performance management.

sustainability_report p.97

Pfizer divested two manufacturing locations in St. Louis, Missouri to Altaris at end of December 2021. Also divested Hangzhou, China facility in Feb 2021.

sustainability_report p.45

Pfizer's 2019 baseline emissions were restated to reflect the Upjohn divestiture and other acquisitions/divestitures. Emission factors updates also applied.

sustainability_report p.46

In 2021, methodology for business travel emissions changed to include radiative forcing in air travel emission factors. 2019 baseline restated, resulting in 80% increase.

sustainability_report p.48

New Tuas, Singapore API manufacturing facility designed with integration of energy-efficient systems and comprehensive metering (target completion 2023). New NYC HQ at Hudson Yards designed to meet/exceed LEED v4 Gold and WELL v2 Pilot Gold standards: lighting power demand 30% below LEEDv4 baseline, low-flow plumbing, advanced energy metering. $401M of 2020 Sustainability Bond proceeds allocated to these environmental projects as of Dec 31 2021.

sustainability_report p.22

Pfizer is RE100 committed to 100% renewable electricity by 2030. In 2021 entered a US virtual PPA delivering 310 MW of new solar to ERCOT grid from 2023, covering ~50% of global electricity. Working to establish a Europe VPPA (~16% of footprint) and to secure RECs for remaining purchased electricity by 2025. Will eliminate remaining 20% via on-site fossil-fuel replacement by 2030. Renewable electricity was 7.6% of total in 2021, down from 9.4% in 2019 baseline.

sustainability_report p.40

Pfizer commits to neutralize unabated emissions with permanent carbon removals at the 2040 Net-Zero target year. Currently developing Net-Zero transition plan including approach to managing residual emissions. Will work with SBTi to validate by January 2024.

sustainability_report p.41

In 2021 Pfizer invested $19M in 80+ energy efficiency projects at 19 manufacturing sites, achieving ~17,000 tCO2e annual reductions. ~46% of savings from HVAC replacement/optimization, 34% from chiller replacements (Belgium, Ireland, Italy, US), remainder from boiler, compressed air, steam, lighting. Projected $2.7M annual operating savings.

sustainability_report p.42

In early 2021 Pfizer concluded a three-year project to replace six coal-fired boilers at Kalamazoo, MI manufacturing site that had operated since 1948-1952, eliminating 10,800 tCO2e GHG emissions, 208 tons of non-GHG emissions, and 1,550 tons of coal ash annually.

sustainability_report p.28

Upstream transport emissions were elevated in 2021 (685k tCO2e vs 509k baseline) due to air-freighted COVID vaccine cold chain and 2021 Suez Canal-driven ocean-to-air shifts. Pfizer is engaging key logistics suppliers (FedEx, UPS, CH Robinson) to develop reduction plans and shift shipments from air to ocean where feasible.

sustainability_report p.34

Pfizer set a 1.5°C-aligned absolute Scope 1+2 GHG reduction target of 46% by 2030 from a 2019 base year, approved by the Science Based Targets initiative in 2020. Base year emissions: Scope 1 702,830 tCO2e, Scope 2 (market) 586,432 tCO2e.

sustainability_report p.35

Pfizer committed in December 2020 to procure 100% renewable energy by 2030 across internal operations, with a 46% absolute reduction in Scope 1+2 emissions from a 2019 baseline. The 2030 target is SBTi-validated as 1.5°C-aligned. Any remaining residual emissions will be offset through carbon credits. Specific PPA/REC procurement instruments are not disclosed in this report.

sustainability_report p.16

Pfizer committed to become carbon neutral across internal operations by 2030, including a 46% absolute reduction in Scope 1 and 2 emissions from a 2019 baseline and 100% renewable energy procurement. Any remaining emissions to be offset via carbon credits. SBTi commended this as an ambitious 1.5°C-aligned target.

sustainability_report p.16

By 2025, Pfizer aims to reduce upstream logistics emissions by 10% and business travel emissions by 25% from a 2019 baseline.

sustainability_report p.16

On November 16, 2020, Pfizer's Upjohn business (off-patent branded and generics) was spun off and combined with Mylan to create Viatris. ESG metrics generally exclude Upjohn going forward, though environmental metrics include Upjohn for continuity with 2012-baseline 2020 goals. This affects year-over-year comparability of social metrics.

sustainability_report p.49

Pfizer reports alignment with UN Sustainable Development Goals 3 (Good Health), 5 (Gender Equality), 8 (Decent Work), 9 (Industry/Innovation), 10 (Reduced Inequalities), 12 (Responsible Consumption), 13 (Climate Action), 16 (Peace/Justice), and 17 (Partnerships).

sustainability_report p.9

In March 2020 Pfizer issued the first biopharmaceutical Sustainability Bond ($1.25bn, 2.625% coupon, due April 2030). As of Dec 31 2020, $43m of net proceeds allocated to environmental projects and $253m to social projects (including replenishing Pfizer Foundation endowment, women's health, AMR, and health infrastructure).

sustainability_report p.17

In December 2020 Pfizer announced its ambition to become carbon neutral across internal operations by 2030, with remaining emissions addressed through high-quality and verifiable offsets.

sustainability_report p.76

Pfizer named to CDP's 2020 Supplier Engagement Leaderboard for the third consecutive year (2018, 2019, 2020) and featured in CDP's Stories of Change.

sustainability_report p.16

Pfizer set 2025 targets to reach 47% global female representation at VP+ (from 38.1% in 2020) and 32% U.S. minority representation at VP+ (from 21.5% in 2020), including doubling of African American/Black and Hispanic/Latino representation.

sustainability_report p.22

2020 GHG footprint (Scope 1, 2, and Scope 3 categories 1-8 and 15) independently assured to limited assurance level pursuant to ISAE 3000 (revised) by ERM CVS. Verification of 2021 data underway.

sustainability_report p.80

Pfizer committed to purchasing 100% renewable energy by 2030 as part of its carbon-neutral pathway.

sustainability_report p.16

Manufacturing at Pfizer Global Supply (PGS) sites accounts for ~70% of direct energy consumption and GHG emissions. Pfizer delivered a 33% Scope 1+2 reduction from 2012 to 2020 via 1,000+ energy projects yielding >$5m annual savings. PGS strategy includes mandated site energy master plans and a GHG KPI tracked on the CFO/EVP Global Supply dashboard.

sustainability_report p.47

Second-generation supply chain goal to catalyse suppliers to establish science-based GHG reduction targets by 2025. 2020 progress: 52% of 111 key suppliers had reduction goals (target was 90%).

sustainability_report p.29

2020 marks Pfizer's first consolidated ESG report, including first SASB disclosure for biotech/pharma, first TCFD-aligned report and integration of ESG into Enterprise Risk Management. 2020 used as baseline for many social and governance metrics.

sustainability_report p.6

Pfizer committed to a 10% reduction in upstream-logistics emissions by 2025 from a 2019 baseline, recognising that indirect (value chain) emissions account for ~80% of its carbon footprint.

sustainability_report p.16

Pfizer engages 111 key suppliers (pharmaceutical ingredients, drug products, packaging, R&D collaborators, freight forwarders) to set GHG reduction goals. As of 2020, 52% had reduction goals (vs 90% target) and the second-generation goal is for suppliers to set science-based targets by 2025. Mechanisms include embedding sustainability criteria in vendor selection, contract clauses, and direct engagement. Recognised on CDP Supplier Engagement Leaderboard 2018-2020.

sustainability_report p.16

Pfizer states that any remaining Scope 1+2 emissions after the 46% absolute reduction by 2030 will be offset through carbon credits. The report does not distinguish removals (DAC, BECCS, biochar) from avoidance offsets and does not disclose volumes, vintages or a quality standard for the credits.

sustainability_report p.16

Pfizer applies the 12 Principles of Green Chemistry to drug development. Example: the enzymatic route to abrocitinib delivered a 60% reduction in CO2 emissions (kg CO2e/kgA) and a 68% reduction in process mass intensity vs the early synthetic route, while eliminating two hazardous substances and replacing halogenated solvents.

sustainability_report p.18

Commitment to drive 64% of suppliers by spend to adopt science-based GHG emission reduction goals by 2025.

sustainability_report p.38

SBTi-approved target to reduce Scope 3 Category 4 (upstream transportation and distribution) emissions 10% by 2025 from 2019 baseline. 2°C aligned.

sustainability_report p.42

Pfizer set a science-based target to reduce Scope 1 and 2 GHG emissions 46% from a 2019 baseline by 2030, validated by SBTi and 1.5°C aligned.

sustainability_report p.35

In December 2020, Pfizer announced ambitious fourth-generation GHG emissions reduction targets, approved by the Science Based Targets Initiative as aligned with a 1.5C trajectory. Commits to be carbon neutral across internal operations (Scope 1+2 market-based) by 2030, 46% absolute reduction from 2019 baseline, and 100% renewable electricity. Also commits to reduce business travel emissions 25% and upstream logistics 10% by 2025 from 2019 baseline.

sustainability_report p.28

In 2020 Pfizer set a science-based target to reduce Scope 1+2 emissions 46% by 2030 from 2019 baseline, approved by SBTi as 1.5°C aligned.

sustainability_report p.32

SBTi-approved supplier engagement target to drive 64% of suppliers of goods and services by spend to adopt science-based GHG reduction targets by 2025. Progress at 29% in 2022 vs 5% baseline.

sustainability_report p.57

Base year emissions (2012) were updated in 2020 due to a baseline adjustment to account for the divestiture of Pfizer's Upjohn division.

sustainability_report p.32

Scope 1 and Scope 2 base year (2012) emissions restated downward to reflect Upjohn divestiture. Scope 1 base year now 964,846 tCO2e; Scope 2 base year 883,814 tCO2e.

sustainability_report p.32

In 2020, Pfizer completed a $1.25 billion ten-year sustainability bond, a first for a biopharmaceutical company, financing environmental and access initiatives.

sustainability_report p.26

Approximately 5% of the 33% Scope 1+2 reduction over the third-generation goal period (2012-2020) is attributed to the impact of the COVID-19 pandemic on global Commercial and Fleet operations in 2020.

sustainability_report p.28

Member of RE100; target 80% renewable electricity by 2025 and 100% by 2030.

sustainability_report p.56

Pfizer commits to purchase 100% renewable electricity by 2030 as part of its SBTi-validated 1.5C-aligned target. In 2020 the company consumed 23,367 MWh of self-generated non-fuel renewable electricity and procured renewable power via supply agreements including wind (UK, Spain), biomass district heat/steam (Sweden), and hydropower-backed green tariffs (Croatia). Total renewable energy was ~128 GWh out of 4.5 TWh consumption. Investments include photovoltaic at Puurs (Belgium) and solar thermal at Freiburg (Germany).

sustainability_report p.19

Pfizer's strategy emphasizes absolute emission reduction over offsets/removals. The 2030 carbon neutral commitment targets a 46% absolute reduction from 2019 baseline plus 100% renewable electricity. The firm originated 2,533 tonnes of Connecticut Class III RECs from cogeneration/efficiency projects in 2020 (sold rather than retired). No durable carbon removal (DAC/BECCS) program is described. Carbon credits are not assumed to count toward compliance under modelled federal carbon pricing scenarios.

sustainability_report p.67

Pfizer Global Supply (manufacturing) accounts for 75% of energy consumption and GHG emissions. In 2020, 57 projects (HVAC optimization, compressed air, heat recovery, lighting upgrades, chilled water improvements) delivered 22,123 tCO2e reductions and $3.2M annual savings on $39.6M invested. Medium/large sites maintain sustainability master plans reviewed at corporate level.

sustainability_report p.47

Three-year project completed early 2021 to replace six coal-fired boilers at Kalamazoo, Michigan with natural gas, eliminating 10,800 mT CO2e annually. Coal had been burned at the site since 1948-1952. Lower-return projects are approved despite long paybacks (10-15 years for some renewable installations).

sustainability_report p.26

Pfizer committed to reduce business travel emissions 25% by 2025 from a 2019 baseline as part of SBTi-validated targets. 2020 business travel emissions were 35,128 tCO2e (heavily reduced by COVID-19).

sustainability_report p.30

Recognizing indirect emissions account for ~80% of carbon footprint, Pfizer commits to catalyze 64% of suppliers (by spend) to adopt science-based GHG reduction targets by 2025. Approach includes embedding environmental sustainability in vendor selection, strengthening contract language, and direct engagement. At end of 2020, 86% of key suppliers were managing environmental impacts and >75% had GHG reduction goals in progress.

sustainability_report p.25

Pfizer commits to reduce emissions from upstream transportation and distribution by 10% by 2025 from a 2019 baseline (SBTi-approved). Upstream T&D was the largest single Scope 3 category outside purchased goods at 723,558 tCO2e in 2020, inflated by dry-ice/COVID vaccine cold-chain logistics.

sustainability_report p.30

SBTi-approved 1.5°C-aligned target to reduce Scope 3 Category 6 (business travel) emissions 25% by 2025 from 2019 baseline.

sustainability_report p.49

Pfizer set internal target to reduce water withdrawal (excluding non-contact cooling water) at manufacturing sites 5% by 2030 vs 2019 baseline. Aligned with SDG 6. Reporting year shows 9% reduction vs baseline.

sustainability_report p.407

In 2020, Pfizer completed a $1.25 billion ten-year sustainability bond, a first for a biopharmaceutical company. As of Dec 31, 2021, $401M allocated to environmental projects.

sustainability_report p.28

2020 GHG footprint (Scope 1, 2, and Scope 3 categories 1-8 and 15) independently assured to limited assurance level by ERM-CVS per ISAE 3000 (revised). 2021 verification underway at report time.

sustainability_report p.80

Pfizer joined RE100, committing to 100% renewable electricity by 2030. Entered VPPA in 2021 covering ~50% of global electricity use once operational in 2023.

sustainability_report p.40

Pfizer set Low 1 target: 100% renewable electricity by 2030, validated by SBTi and part of RE100 commitment. Base year 9.5% renewable share (2019). Reporting year 2024: 14.4% achieved.

sustainability_report p.334

Pfizer set Abs 5 target (well-below 2°C): 25% absolute reduction in Scope 3 Category 6 (business travel) by 2025 from 2019 baseline (421,399 tCO2e). As of end 2024, 221% of target achieved; emissions 55% below 2019 baseline.

sustainability_report p.320

Pfizer set Abs 4 target (well-below 2°C): 10% absolute reduction in Scope 3 Category 4 (upstream transportation) by 2025 from 2019 baseline (200,873 tCO2e). As of end 2024, 233% of target achieved; emissions 23% below 2019 baseline.

sustainability_report p.316

In November 2020 Pfizer set near-term science-based targets validated by SBTi: reduce Scope 1+2 absolute GHG emissions 46% by 2030 from 2019 baseline (1.5°C aligned); reduce Scope 3 Cat 4 upstream transportation 10% by 2025; reduce Scope 3 Cat 6 business travel 25% by 2025; 64% of suppliers by spend to set SBTi-aligned targets by 2025.

sustainability_report p.310

Pfizer set and obtained SBTi validation (1.5°C aligned) for Abs 3 target: 46% absolute reduction in Scope 1 and 2 emissions by 2030 from a 2019 baseline. Base year: 1,266,345 tCO2e combined S1+S2 (market). As of end 2024, achieved 32.27% of target (15% reduction from baseline).

sustainability_report p.311

Pfizer set a target to engage 64% of suppliers by spend to adopt science-based GHG reduction goals by 2025, from a 2019 base of 5%. At end of 2022, 29% had obtained or committed to SBTi approval.

sustainability_report p.57

Pfizer set a 1.5°C-aligned Scope 3 Cat 6 (business travel) reduction target of 25% by 2025 from a 2019 base year of 359,523 tCO2e. Reporting year value: 80,167 tCO2e — 78% below baseline, aided by pandemic travel restrictions.

sustainability_report p.49

Pfizer set a target to source 100% renewable electricity by 2030 (80% by 2025), with 9.5% renewable electricity at 2019 base year. Pfizer joined RE100 in January 2022. Reporting year achievement: 6.9%, below base year due to changes in green power procurement.

sustainability_report p.56

Pfizer set a 2°C-aligned Scope 3 Cat 4 (upstream transportation) reduction target of 10% by 2025 from a 2019 base year of 611,059 tCO2e. Reporting year value: 712,318 tCO2e — emissions increased due to COVID-19 vaccine cold-chain air distribution.

sustainability_report p.42